The associations called a rule that labs use a CE-IVD marked device over an LDT "groundless discrimination."
The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.
The firm's core laboratory revenues declined 1 percent, while molecular laboratory sales were up 4 percent.
The firm currently has various assays in its clinical trial pipeline from its North Carolina headquarters.
UPDATE: Labcorp Q1 Revenues Rise 5 Percent
The firm reported on Tuesday that its diagnostics revenues rose 6 percent from a year ago while its biopharma lab services revenues rose almost 2 percent.
Thermo Fisher Scientific Lowers 2025 Adjusted EPS Guidance in Light of Tariffs, US Policy Changes
Premium
The new guidance reflects the impact from China-related tariffs as well as dampening US grant funding, partially offset by the firm's mitigation actions.